Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2020-04-24

Original market date: See footnote 1

2020-04-24

Product name:

MAYZENT

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02496437

Product Monograph/Veterinary Labelling:

Date: 2023-11-20 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

NOVARTIS PHARMACEUTICALS CANADA INC
100 700 Rue Saint-Hubert
Montreal
Quebec
Canada H2Y 0C1

Class:

Human

Dosage form(s):

Tablet

Route(s) of administration:

Oral

Number of active ingredient(s):

1

Schedule(s):

Prescription

 

American Hospital Formulary Service (AHFS): See footnote 3

92:20.00 

Anatomical Therapeutic Chemical (ATC): See footnote 4

L04AE03 SIPONIMOD

Active ingredient group (AIG) number:See footnote5

0162037002

List of active ingredient(s)
Active ingredient(s) Strength
SIPONIMOD 2 MG

Risk Management Plans See footnote 7

A Risk Management Plan (RMP) for this product was submitted.

Additional Risk Minimization Measures
Healthcare Professional Education
Patient Education
Version 4.0.2
Date modified: